N-[2-(1H-吲哚-3-基)乙基]-N-甲基-2-丙胺 | 96096-52-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: N-[2-(1H-吲哚-3-基)乙基]-N-甲基-2-丙胺
• 英文名称: N-methyl-N-isopropyltryptamine
• 英文别名: MiPT；N-[2-(1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
• CAS: 96096-52-5
• 化学式: C₁₄H₂₀N₂
• 分子量: 216.326
• InChiKey: KTQJVAJLJZIKKD-UHFFFAOYSA-N

物化性质

• 沸点：
  353.7±25.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  苄基(2-(1H-吲哚-3-基)乙基)氨基甲酸酯 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 15.5h， 生成 N-[2-(1H-吲哚-3-基)乙基]-N-甲基-2-丙胺
  参考文献：
  名称：

  Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents

  摘要：

  Eight N-methyl-N-isopropyltryptamines (MIPTs) possessing various aromatic oxygen substituents were prepared, characterized, and evaluated for hallucinogenic activity in man. In at least two instances (the Ar H and the Ar 5-OCH3, 1 and 4) the unsymmetrical nitrogen substitution led to a substantial increase in potency as well as oral activity when compared to the symmetrical dimethyl homologues. Qualitatively, 4-hydroxy-N-methyl-N-isopropyltryptamine (2) was the most interesting in overall effect, producing a classic hallucinogenic profile. The 5-methoxy congener 4 resulted in a state characterized by heightened conceptual stimulation lacking in visual phenomena. Other members of the series exhibited diminished effects.

  DOI：

  10.1021/jm00145a007

文献信息

• TRYPTAMINE PRODRUGS
  申请人：Field Trip Psychedelics Inc.

  公开号：US20210403425A1

  公开（公告）日：2021-12-30

  The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.

  本发明提供了一种色胺前药化合物。化合物由公式(I)表示，其中每个符号如说明书中所述，或其盐或离子，被转化为具有5HT2A受体激动剂活性的活性物质，并用作抗抑郁剂的药物。
• Methods of treating food allergy conditions
  申请人：Palo Alto Investors LP

  公开号：US11045454B2

  公开（公告）日：2021-06-29

  Methods for treating a subject for a food allergy condition are provided. Aspects of the methods include administering to a subject in need thereof a psychedelic agent in a manner effective to treat the subject for a food allergy condition. Effective administration of a psychedelic agent may include administering the psychedelic agent in an amount effective to treat the subject for the food allergy condition. In some instances, the subject is known to have a food allergy condition.

  本文提供了治疗食物过敏症的方法。这些方法的各个方面包括以有效治疗食物过敏症的方式向有需要的受试者施用迷幻剂。有效施用迷幻剂可包括以有效治疗受试者食物过敏症的量施用迷幻剂。在某些情况下，受试者已知患有食物过敏症。
• Tryptamine prodrugs
  申请人：Field Trip Psychedelics Inc.

  公开号：US11292765B2

  公开（公告）日：2022-04-05

  The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.

  本发明提供了一种色胺原药化合物。 由式（I）（其中各符号如说明书所述）代表的化合物或其盐或齐聚物转化为具有 5HT2A 受体激动剂活性的活性物质，可用作治疗抑郁症的药物。
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• Methods of Treating Food Allergy Conditions
  申请人：Palo Alto Investors LP

  公开号：US20200179349A1

  公开（公告）日：2020-06-11

  Methods for treating a subject for a food allergy condition are provided. Aspects of the methods include administering to a subject in need thereof a psychedelic agent in a manner effective to treat the subject for a food allergy condition. Effective administration of a psychedelic agent may include administering the psychedelic agent in an amount effective to treat the subject for the food allergy condition. In some instances, the subject is known to have a food allergy condition.